TY  - JOUR
AU  - Fakhouri, Fadi
AU  - Hourmant, Maryvonne
AU  - Campistol, Josep M
AU  - Cataland, Spero R
AU  - Espinosa, Mario
AU  - Gaber, A Osama
AU  - Menne, Jan
AU  - Minetti, Enrico E
AU  - Provôt, François
AU  - Rondeau, Eric
AU  - Ruggenenti, Piero
AU  - Weekers, Laurent E
AU  - Ogawa, Masayo
AU  - Bedrosian, Camille L
AU  - Legendre, Christophe M
PY  - 2016
DO  - 10.1053/j.ajkd.2015.12.034
UR  - http://hdl.handle.net/10668/9943
T2  - American journal of kidney diseases : the official journal of the National Kidney Foundation
AB  - Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end-organ damage. Eculizumab, a terminal complement inhibitor...
LA  - en
KW  - Eculizumab
KW  - Soliris
KW  - TMA response
KW  - adults
KW  - atypical hemolytic uremic syndrome (aHUS)
KW  - clinical trial
KW  - hematologic normalization
KW  - hemoglobin
KW  - kidney disease
KW  - lactate dehydrogenase (LDH)
KW  - platelet count
KW  - renal function
KW  - terminal complement inhibitor
KW  - thrombotic microangiopathy (TMA)
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Atypical Hemolytic Uremic Syndrome
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Remission Induction
KW  - Young Adult
TI  - Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
TY  - research article
VL  - 68
ER  -